Steroid injection with oral administration in preventing stricture after endoscopic submucosal dissection for esophageal carcinoma. - Stellar Study

Kakushima Naomi0 个研究点目标入组 30 人开始时间: 2023年1月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients diagnosed as esophageal carcinoma.
•2. Depth up to cT1b(SM1, <200micrometers)
•3. No metastasis confirmed by neck to abdominal CT.
•4. Tumor with >=1/2 circumference or simultaneous resection of multiple adjacent lesions which are expected to have ulcer with >3/4 circumference after ESD.
•5. Patients who are indicated and scheduled for esophageal ESD.
•6. ECOG performance status of 0 or1.
•7. Age >= 18.
•8. Patients who provide written informed consent.
•9. Patients who can go to the outpatient clinic according to the clinical research schedule

•1. Diabetes Mellitus with HbA1c >=8%.
•2. Severe liver, renal, cardiovascular disease.
•3. Patients who are receiving continuous systemic administration of steroids or other immunosuppressants at the time of informed consent
•4. Patients with infectious diseases that require systemic treatment.
•5. Patients who have allergy to triamcinolone, prednisolone, and sulfamethoxazole trimethoprim.
•6. Patients taking desmopressin acetate.
•7. Patients who have active HBV hepatitis.
•8. Patients who are pregnant.
•9. Patients who the investigator judges inappropriate to participate in this study.

发起方

Kakushima Naomi